September 18, 2009 at 13:25 PM EDT
(IMGN) Amgen Taps ImmunoGen License
Yesterday, ImmunoGen Inc. (IMGN) announced that it has licensed its technology to Amgen Inc. (AMGN) to develop anticancer drugs. The deal allows Amgen exclusive rights to use ImmunoGen’s maytansinoid targeted antibody payload [TAP] technology for developing anticancer therapeutics to an undisclosed target found on solid tumors. According to the terms of the deal, ImmunoGen will receive [...] (IMGN) Amgen Taps ImmunoGen License
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here